Coeptis Therapeutics Holdings, Inc.

As of April 1, 2024, Coeptis Therapeutics Holdings, Inc. shows a mildly bearish trend overall, with weekly MACD and KST indicators confirming this outlook, while daily moving averages suggest short-term strength amidst mixed signals.

Coeptis Therapeutics Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $3 million as of March 2025, with a market cap of $28.85 million. Key financial metrics include a negative P/E ratio, a dividend yield of 0.00%, and a return on equity of -167.63%.

As of Jun 18, Coeptis Therapeutics Holdings, Inc. has a market capitalization of 28.85 million, with net sales of 0.06 million and a net profit of -11.30 million over the last four quarters. The company's shareholder's funds are 5.29 million, and total assets are 11.01 million as of Dec 24.